Leerink upgraded Amylyx (AMLX) to Outperform from Market Perform with a $10 price target
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx doses first participant in Phase 3 LUCIDITY trial of avexitide
- Biotech Alert: Searches spiking for these stocks today
- Amylyx doses first participant in LUMINA trial
- Amylyx upgraded to Outperform from Neutral at Mizuho
- Cautious Hold Rating for Amylyx Pharmaceuticals Amid Key Clinical Updates and Stable Financial Position